Diffuse Large B Cell Lymphoma
269
61
88
67
Key Insights
Highlights
Success Rate
78% trial completion
Published Results
20 trials with published results (7%)
Research Maturity
67 completed trials (25% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
7.1%
19 terminated out of 269 trials
77.9%
-8.6% vs benchmark
7%
19 trials in Phase 3/4
30%
20 of 67 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 67 completed trials
Clinical Trials (269)
IOMAB-CAR-T Followed by CAR-T Cell Therapy in R/R DLBCL
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma
Geriatric-guided Care Versus Conventional Care in Elderly Unfit/Frail Patients With Diffuse Large B-cell Lymphoma in First Line Treatment
Leukapheresis for CAR or Adoptive Cell Therapy Manufacturing
External Beam Radiotherapy Followed by Bispecific Antibody Therapy for Relapsed/Refractory DLBCL
SynKIR-310 for Relapsed/Refractory B-NHL
Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells
Study of Lenalidomide in Combination With RICE With Lenalidomide Maintenance Post-Auto Transplant for DLBCL
Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma
TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma
Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy
CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell Transplant
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
A Study of Ultra-fraction Radiotherapy Bridging CART in R/R DLBCL
Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom
A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma
Treatment of Patients With Diffuse Large B Cell Lymphoma Who Are Not Suitable for Anthracycline Containing Chemotherapy